Clinical trials
Glioblastoma clinical trials
Below are recruiting glioblastoma clinical trials, each written for real people, not researchers. We’re tracking 316 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT04863950RecruitingPhase 2
Imipramine plus lomustine for recurrent glioblastoma
This study tests whether combining imipramine (a medicine used for mood and sometimes nerve pain) with lomustine (a chemotherapy) can slow or treat recurrent glioblastoma that has come back after standard radiation and temozolomide. It is mainly for adults who are well enough to travel through treatment and monitoring scans and blood tests.
San Antonio, TexasAges Any age - NCT06556563RecruitingPhase 3
Optune with chemo and immunotherapy for new glioblastoma
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
Phoenix, ArizonaAges 18 years+ - NCT06558214RecruitingPhase 2
Laser surgery, Optune device, and Keytruda for recurrent glioblastoma
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Gainesville, FloridaAges 18–90 - NCT06533163Recruiting
Magnetic therapy for new glioblastoma
This trial tests a new low-intensity magnetic treatment (like a gentle magnetic pad placed on your head) for people with a newly diagnosed, aggressive brain tumor called glioblastoma. It aims to see if different amounts of exposure to this therapy are safe and help slow tumor growth.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06102525RecruitingPhase 1/Phase 2
Testing RZ-001 with valganciclovir for glioblastoma
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
IncheonAges 18 years+ - NCT06512311Recruiting
Personalized drug testing for newly diagnosed glioblastoma
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
Vienna, State of ViennaAges 18–75 - NCT06504381RecruitingPhase 1/Phase 2
DB107 and radiation therapy for high-grade glioma
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06466031Recruiting
PET/MRI for guiding glioblastoma surgery
This trial tests whether a special PET scan combined with MRI can help guide surgery for glioblastoma. It is for people with a newly diagnosed, single tumor who are candidates for surgery.
Lodz, Łódź VoivodeshipAges 18–70 - NCT06410248RecruitingPhase 1
Triapine with temozolomide for recurrent glioblastoma
This trial is testing a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06385132Recruiting
Studying mental health in brain and head/neck cancer
This study looks at the emotional and mental health of people with glioblastoma (a type of brain tumor) or head and neck cancer who are getting a long course of radiation therapy. The goal is to understand how they are feeling so doctors can provide better support.
RomaAges 18–75 - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06222138Recruiting
Biomarker study of TTFields in newly diagnosed glioblastoma
This trial looks at how well Tumor Treating Fields (TTFields) therapy works for people with newly diagnosed glioblastoma. Researchers will study blood and tumor samples to find markers that might predict how well the treatment works.
ToulouseAges 18 years+ - NCT06132438RecruitingPhase 1
New immunotherapy for CMV-positive glioblastoma
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
Liverpool, New South WalesAges 18–100 - NCT06069726RecruitingPhase 2
Testing atezolizumab for recurrent glioblastoma
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
San Francisco, CaliforniaAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT06059690RecruitingPhase 1/Phase 2
Imaging brain tumors to guide glioblastoma treatment
This trial studies a special imaging scan that combines MRI and PET to find active tumor areas in patients with glioblastoma. It aims to see if the scan can help identify the most aggressive parts of the tumor for surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT06039709RecruitingPhase 1
Sound wave therapy for recurrent glioblastoma
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
Charlottesville, VirginiaAges 18–80 - NCT05904119RecruitingPhase 3
Lomustine with or without re-irradiation for recurring glioblastoma
This trial studies whether adding repeat radiation (called re-irradiation) to the chemotherapy medicine lomustine can slow or control glioblastoma that has returned or progressed after standard treatment. It’s designed for people whose tumor comes back at least 6 months after their last radiation.
InnsbruckAges 18 years+ - NCT05908669Enrolling by invitation
MRI tracking of radiotherapy changes in newly diagnosed brain cancer
This study uses special MRI imaging with deuterium to see how radiotherapy affects newly diagnosed glioblastoma (GBM) with an IDH-wildtype tumor. It may help doctors better understand treatment response and timing, potentially improving how radiotherapy is planned.
AarhusAges 18 years+
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma?
- Yes. Clin2 currently lists 316 recruiting glioblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.